Epigenetics Drugs and Diagnostic Technologies Market, by Type (Epigenetic Drugs, (DNMT Inhibitors (Azacitidine and Decitabine), HDAC Inhibitors (Vorinostat, and Romidepsin) and Others) and Epigenetics Diagnostic Technologies (DNAMethylation and CHIP Technology) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jul 2023

Code : CMI4026

Pages :160

Formats :

Excel and PDF

Industry : Biotechnology

Epigenetics Drugs and Diagnostic Technologies MarketSize and Trends

The global epigenetics drugs & diagnostic technologies market is estimated to be valued at US$ 11.2 billion in 2023 and is expected to exhibit a CAGR of 18.8 % during the forecast period (2023-2030).

Global Epigenetics Drugs & Diagnostic Technologies Market: Market Trends

Launch of newer epigenetics technologies

Launch of newer epigenetics technologies can drive growth of market. For instance, on February 24, 2021, Twist Bioscience, a U.S.-based semiconductor-based synthetic DNA manufacturing company announced the launch of Twist NGS Methylation Detection System, a robust, end-to-end sample preparation and target enrichment solution for identifying methylated regions in the human genome. In partnership with New England Biolabs, a U.S. based recombinant and native enzyme reagents supplier, it has developed a state-of-the-art system, to identify and accurately evaluate methylation patterns that enable our customers to create better tests and/or conduct research more efficiently. In addition, the superior results produced through this system provide incentive for customers using SNP microarray technology to switch to using Twist products plus sequencing.Acquisition strategy by key market players

Strategies like acquisitions by key market players can drive the market growth. For instance, on October 27, 2020, Exact Sciences, a U.S.-based biotechnology research company, and Thrive Earlier Detection Corp., a U.S.-based healthcare company, announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive Earlier Detection Corp for cash and stock consideration of up to US$ 2.15 billion. Combining Thrive Earlier Detection Corp’s pioneering early-stage screening test, CancerSEEK, with Exact Sciences' scientific platform, clinical organization, and commercial infrastructure can establish exact sciences as a leading competitor in blood-based, multi-cancer screening.